protein
| binding in its non-phosphorylated form to EIF4E |
|
interacting with RPTOR |
|
represses translation initiation by binding to eukaryotic initiation factor 4E (EIF4E) |
|
EIF4E2 interaction with EIF4EBP1 is necessary for this observed impaired signaling to EIF4EBP1 and RPS6KB1 |
|
EIF4EBP1 inhibits cap-dependent translation by binding to the EIF4E translation initiation factor |
|
activity of EIF4E is under homeostatic control via the regulation of the levels of its repressor protein EIF4EBP1 through ubiquitination |
|
PPM1G binds to EIF4EBP1 in cells (PPM1G is a novel regulator of cap-dependent protein translation by negatively controlling the phosphorylation of EIF4EBP1) |
|
MTOR controls mitochondrial activity and biogenesis by selectively promoting translation of nucleus-encoded mitochondria-related mRNAs via inhibition of the eukaryotic translation initiation factor EIF4EBP1, EIF4EBP2 |
|
RPTOR in MTOR complex 1 is believed to recruit EIF4EBP1, facilitating phosphorylation of EIF4EBP1 by the kinase MTOR |
|
GSPT2 biomarker for hepatocellular carcinoma, influencing cell cycle and phosphoralation status of EIF4EBP1 |
|
MTOR activation inhibits eukaryotic translation initiation factor 4E-binding protein (EIF4EBP1) and activates ribosomal protein S6 kinase 1 (RPS6KB1), both of which stimulate translation |
|
regulation of EIF4EBP1 in skeletal muscle may serve as an important conduit through which MTOR controls metabolism |
|
translational control by EIF4EBP1 downstream of MTOR effects the expression of neuroligin 1 and excitatory synaptic transmission in the spinal cord, and thereby contributes to enhanced mechanical nociception |
|
EIF4EBP1 has tumor suppressor activity by inhibiting EIF4E and, thus, blocking mRNA translation and proliferation |
|
ability of EIF4E to recognize the cap is prevented by its binding to EIF4E binding protein (EIF4EBP1), which thereby inhibits cap-dependent translation by sequestering EIF4E |